Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0100
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question ; volume:78 ; number:3 ; day:20 ; month:8 ; year:2022 ; pages:441-445 ; date:12.2022
Endocrine ; 78, Heft 3 (20.8.2022), 441-445, 12.2022
- Creator
-
Caramella, Irene
Dalla Volta, Alberto
Bergamini, Marco
Cosentini, Deborah
Valcamonico, Francesca
Berruti, Alfredo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12020-022-03166-w
- URN
-
urn:nbn:de:101:1-2023012021145216846138
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Caramella, Irene
- Dalla Volta, Alberto
- Bergamini, Marco
- Cosentini, Deborah
- Valcamonico, Francesca
- Berruti, Alfredo
- SpringerLink (Online service)
Other Objects (12)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2